CORE--CLINICAL

临床核心的总体目标是招募、评估和 跟踪阿尔茨海默病（AD）患者， 和正常对照，以提供良好表征的受试者用于临床 研究项目和随后的病理学研究。 具体目标 a）招募、评价和系统地纵向跟踪 患有AD和相关痴呆症的患者，B）招募和 评估一系列认知正常的社区居住者（N=400）或 养老院（N=50）志愿者对照受试者，他们同意 预先安排的尸检，c）提供系统的纵向随访， 认知功能（每年）和神经学结果（每隔一年） 对照受试者，d）维持临床、神经心理学和 AD、相关痴呆症和对照行为数据库 e）增加前来尸检的AD患者的数量， 然后研究神经学、神经心理学和 行为结果，因为它们与定量组织病理学和 尸检发现的区域变化，f）继续参与 多中心治疗药物试验，g）继续参与 联合体项目，包括AD合作研究和CERAD，h） 增加AD和相关疾病患者的数量（少数民族和 农村）在我们的卫星诊断和治疗诊所，和i）登记 少数民族和农村控制科目，通过我们的卫星诊断， 治疗诊所。 我们目前在记忆障碍诊所跟踪了500名患者。 我们有 招募了317名认知正常的志愿者作为对照， 同意死后捐献大脑

The overall objective of the Clinical Core is to recruit, evaluate and follow patients with Alzheimer's disease (AD), related dementing disorders and normal controls to provide well-characterized subjects for clinical research projects and subsequent pathologic studies. The specific aims are a) to recruit, evaluate and systematically longitudinally follow patients with AD and related dementing disorders, b) to recruit and evaluate a series of cognitively normal community-dwelling (N=400) or nursing home (N=50) volunteer control subjects who have consented to prearranged autopsy, c) to provide a systematic longitudinal follow-up of cognitive function (annual) and neurologic findings (every other year) of control subject, d) to maintain a clinical, neuropsychologic and behavioral database on AD, related dementing disorders, and control subjects, e) to increase the number of AD patients who come to autopsy and then investigate associations between neurologic, neuropsychologic, and behavioral findings as they relate to quantitative histopathologic and regional changes found at autopsy, f) to continue participation in multicenter therapeutic drug trial, g) to continue participation in consortium projects including the AD Cooperative Studies and CERAD, h) to increase the number of AD and related disorders patients (minority and rural) in our Satellite Diagnostic and Treatment Clinics, and i) to enroll minority and rural control subjects through our Satellite Diagnostic and Treatment Clinics. We presently follow 500 patients in our Memory Disorders Clinic. We have recruited 317 cognitively normal volunteer control subjects, all of whom have consented to brain donation at death.